The filler news is the bigger shift. Evolus has sold Evolysse since it launched, and the company says more than 3,500 facilities have bought it across five quarters. Reorder rates are moving closer to Jeuveau levels, and CEO David Moatazedi said Evolysse is approaching mid-single-digit share of the filler market.
What changed
Evolus has built its business on Jeuveau, its botulinum toxin for frown lines between the eyebrows. Filler is the second leg. The company has sold hyaluronic acid fillers in the U.S. and Europe, and it expects international operations to be 10% of revenue this year.
Sculpt is the next product. Evolus aims it at the mid-face. CFO Tatjana Mitchell said the segment addresses 40% to 50% of the filler market. Chief Medical Officer Rui Avelar said Sculpt is designed to give more projection than the existing fillers. A lip filler follows in 2028.
Moatazedi described the filler market as stabilized after a softer stretch. He put it roughly flat to slightly growing this year, with unit volume holding near flat. Patient volume, he said, could be growing in the mid- to high-single digits. Clinics are using less filler per visit than they did during the post-COVID boom, and patients want a more natural look.
What it means for practices
This is analysis. A mid-face filler is a product many injectors already buy from someone else, so the question for an owner is whether Evolus can win that slot from an incumbent. Evolus is betting that a clinic already buying Jeuveau and Evolysse will consolidate its filler spend with one supplier. Moatazedi said as much, describing Sculpt as a way for clinics to shift more of their filler business to Evolus.
The company is also paying clinics to buy more now. Evolus ran a portfolio growth rebate in the first half. Moatazedi said accounts in that program were the fastest-growing part of the business. Mitchell said the company will repeat the six-month program in the second half and test a separate offer for another group of accounts. If you run a practice that already carries Evolus products, that rebate is the nearest lever to pull.
Avelar also raised a patient-side point worth taking seriously. Clinics are seeing patients on GLP-1 drugs who worry about losing facial volume. Evolus has put the GLP-1 mention into the Evolysse label language and into advertising it developed with clinics, Moatazedi said. Whether that message converts patients is unknown, and the company gave no numbers on it.
What owners can do now
Ask your Evolus rep for the terms of the second-half portfolio rebate in writing, including the qualifying purchase threshold and whether it stacks with existing pricing.
If you inject mid-face volume with a competing filler, start tracking your cost per syringe and reorder pattern now. That gives you a baseline to test Sculpt against once it is available.
Confirm your state's rules on advertising claims before using any GLP-1 language in marketing, since the company has put that language in its own materials.
What we don't know yet
The filing-level detail is thin. The source gives no Sculpt pricing, no trial data, no regulatory submission date and no indications beyond "mid-face. The approval status is described only as pending, and the source does not say which regulator is reviewing it. The company says Estyme is expected to win approval in Canada, Australia and New Zealand by 2028, but it gives no U.S. timing for that product.
Evolus also described early work on a skin-quality product called Profhilo and a hair-rejuvenation program. Human data on that work is expected around the end of 2028. Evolus is also looking for a biostimulator through a deal, with no target named.
The guidance reaffirmation is the number to watch. Revenue growth of 14% through nine months sits above the 11% to 13% full-year range, which implies a slower fourth quarter. The source does not explain that gap.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.